NGL Fine-Chem Limited

NGLFINE

INE887E01022

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 11:00:49 11/06/2024 BST			5-day change	1st Jan Change
2,379 ^INR	+0.47%		+7.87%	+6.61%

05-28	Transcript : NGL Fine-Chem Limited, Q4 2024 Earnings Call, May 28, 2024
05-22	NGL Fine-Chem Limited Recommends Final Dividend for the Year Ended March 31, 2024	CI

NGL Fine-Chem Limited Appoints Esha Kulkarni as Compliance Officer in Place of Rahul Nachane

April 05, 2017 at 07:42 am

NGL Fine-Chem Limited announced that Esha Kulkarni has been appointed as a compliance officer in place of Rahul Nachane with effect from April 2017.

Latest news about NGL Fine-Chem Limited

Transcript : NGL Fine-Chem Limited, Q4 2024 Earnings Call, May 28, 2024	05-28
NGL Fine-Chem Limited Recommends Final Dividend for the Year Ended March 31, 2024	05-22	CI
NGL Fine-Chem Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	05-21	CI
NGL Fine-Chem Limited Approves the Appointment of Dhananjay Mungale as Independent Director	04-19	CI
Crisil Keeps NGL Fine-Chem Rating at BBB+; Outlook Stable	03-29	MT
NGL Fine-Chem Limited Announces Retirement of Milind Shinde as Independent Director, with Effect from March 31, 2024	03-28	CI
NGL Fine-Chem Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-12	CI
Transcript : NGL Fine-Chem Limited, Q2 2024 Earnings Call, Nov 20, 2023	11-20
NGL Fine-Chem Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	04/08/23	CI
Crisil Keeps SME 1 Rating on NGL Fine-Chem	18/07/23	MT
Transcript : NGL Fine-Chem Limited, Q4 2023 Earnings Call, May 19, 2023	19/05/23
NGL Fine-Chem Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	15/05/23	CI
NGL Fine-Chem Limited Recommends Final Dividend for the Financial Year Ended on March 31, 2023, Payable on or After September 4, 2023	15/05/23	CI
ICRA Affirms NGL Fine-Chem Rating at BBB+	30/03/23	MT
NGL Fine-Chem Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	10/02/23	CI
Crisil Keeps NGL Fine-Chem Rating at BBB+; Lowers Outlook to Stable	12/01/23	MT
Transcript : NGL Fine-Chem Limited, Q3 2022 Earnings Call, Nov 17, 2022	17/11/22
NGL Fine-Chem Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	28/10/22	CI
Transcript : NGL Fine-Chem Limited, Q1 2023 Earnings Call, Aug 17, 2022	17/08/22
NGL Fine-Chem Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	11/08/22	CI
NGL Fine-Chem Limited Announces Resignation of K.V. Subramanian as Independent Director	10/08/22	CI
NGL Fine-Chem Limited Approves Final Dividend for the Financial Year Ended 31 March, 2022	01/07/22	CI
Crisil Keeps SME 1 Rating on NGL Fine-Chem; Shares Fall 5%	20/06/22	MT
Transcript : NGL Fine-Chem Limited, Q4 2022 Earnings Call, May 04, 2022	04/05/22
NGL Fine-Chem Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2022	02/05/22	CI

NGL Fine-Chem Limited is an India-based company, which is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health. The Company caters to various global companies to custom manufacture pharmaceuticals. Its products include APIs Animal Health, APIs Human Health, Intermediates and Specialty Chemicals and Finished Dosage Form. The APIs Animal Health products include Homidium Chloride, Nitroxynil, Clorsulon, Parvaquone, Buparvaquone, Isometamidium Chloride Hydrochloride, Toldimfos Sodium, Butaphosphan, Imidocarb Dipropionate, Triclabendazole, Rafoxanide, Diminazene Aceturate, S-Methoprene, Carprofen and others. The APIs Human Health products include Nitazoxanide and Atovaquone. The Intermediates and Specialty Chemicals product includes 1,4,7-Trimethyl-1,4,7-Triazacylononane and N-Ethyl Glucamine. The Finished Dosage Form products include Diminazene Aceturate Granules and Homidium Chloride Tablets. It has manufacturing plants located around Mumbai.

Sector

Pharmaceuticals

Calendar

31/07/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Veterinary Drugs

	1st Jan change	Capi.
NGL FINE-CHEM LIMITED	+6.61%	175M
ZOETIS INC.	-9.39%	81.6B
ELANCO ANIMAL HEALTH INCORPORATED	+22.42%	9.01B
BLUESTAR ADISSEO COMPANY	+24.50%	3.69B
VIRBAC	-1.81%	3.25B
VETOQUINOL SA	+0.98%	1.3B
JINYU BIO-TECHNOLOGY CO., LTD.	-26.00%	1.23B
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.	-29.34%	1.18B
WUHAN KEQIAN BIOLOGY CO.,LTD	-23.11%	1B
SWEDENCARE AB	+4.41%	945M

Veterinary Drugs